A polyclonal antibody for kiwifruit ringspot virus and its preparation method and application
By preparing and applying kiwi fruit ring-spot virus polyclonal antibodies, the existing detection methods are time-consuming and labor-intensive and technically professional problems are solved, and fast, accurate and simple detection is achieved, filling the gap in polyclonal antibody preparation technology and improving detection Efficiency and accuracy.
Patent Information
- Application Number
- CN202310713563.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-15
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-06-15
AI Technical Summary
The existing kiwi fruit ring-spot virus detection methods are time-consuming, labor-intensive, high equipment requirements, and professional technically, making them difficult to operate in the field. They lack polyclonal antibody preparation technology, which affects the accuracy and efficiency of the detection.
Using polyclonal antibody preparation method, AcCRaV-CP target gene fragment was amplified by reverse transcription PCR, linked to expression vectors, transfected with E. coli, induce protein expression and purification, and a high-titer kiwi fruit ring-plaque virus polyclonal antibody was prepared. For fast and accurate detection.
It realizes the detection of kiwi fruit ring-spot virus with high sensitivity, high specificity and strong stability, fills the gap in polyclonal antibody preparation technology, provides a simple and economical detection solution, suitable for field operations.
Smart Images

Figure CN116970075B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering, and in particular to a polyclonal antibody of kiwifruit ringspot virus and a preparation method and application thereof. Background Art
[0002] Kiwifruit is a nutritious economic fruit. It is popular among the public because its flesh is rich in vitamin C, minerals and dietary fiber. It is very beneficial to human health. Viruses are important microbial pathogens that infect kiwifruit, reducing kiwifruit yield, quality and economic benefits, and seriously threatening the development of the kiwifruit industry. Actinidiachloroticringspot-associatedvirus AcCRaV is a virus that specifically infects kiwifruit. It is common in kiwifruit producing areas and is often combined with other viruses to infect kiwifruit. When kiwifruit is infected with AcCRaV, it often shows symptoms such as leaf chlorosis, mottle and ring spots, which seriously affect the yield and quality of kiwifruit.
[0003] Currently, the main method for detecting AcCRaV is to use virus-specific primers to perform reverse transcription polymerase chain reaction (RT-PCR). This method usually has high sensitivity, but it has the disadvantages of being time-consuming and labor-intensive, requiring high instrumentation and equipment, being too professional, and difficult to operate in the field. Summary of the invention
[0004] In order to solve the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a polyclonal antibody against kiwifruit ringspot virus and a preparation method and application thereof, and to use the polyclonal antibody as a detection reagent for accurate and rapid detection of kiwifruit ringspot virus.
[0005] The technical solution of the present invention to solve the above technical problems is as follows:
[0006] A method for preparing a polyclonal antibody of kiwifruit ringspot virus comprises the following steps:
[0007] (1) Using total RNA of kiwifruit infected with kiwifruit ringspot virus as template to prepare template DNA;
[0008] (2) Using the template DNA prepared in step (1) as a template, AcCRaV-BamH IF / Xho IR primers are used to continue PCR amplification to obtain the AcCRaV-CP target gene fragment;
[0009] (3) Connecting the AcCRaV-CP target gene fragment to the expression vector to obtain a recombinant vector, and then transfecting the recombinant vector into Escherichia coli to induce protein expression and purification to obtain the recombinant protein;
[0010] (4) Using the recombinant protein obtained in step (3), a polyclonal antibody against kiwifruit ringspot virus is prepared.
[0011] Furthermore, the specific process of step (1) is as follows: using the total RNA of kiwifruit infected with kiwifruit ringspot virus as a template, reverse transcription is performed to prepare cDNA, AcCRaV-CP-F-933 / AcCRaV-CP-R-933 primers are used for PCR amplification, and the codon of the amplified product is optimized to obtain template DNA.
[0012] Furthermore, the sequence of AcCRaV-CP-F-933 is: 5'-TTAAGTAGAAGAACCACAATAT-3', and the sequence of AcCRaV-CP-R-933 is: 5'-ATGCCAAAGCCTATGCAAG-3'.
[0013] Furthermore, the PCR amplification conditions in step (1) are:
[0014] The amplification system included: 1 μL cDNA, 1 μL AcCRaV-CP-F-933, 1 μL AcCRaV-CP-R-933, 12.5 μL 2× Taq Master Mix, 9.5 μL ddH2O;
[0015] The amplification program was as follows: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 54°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
[0016] Furthermore, in step (2), the sequence of AcCRaV-BamH IF is: 5'-CGGGATCCATGCCGAAGCCCATGCAGG-3', and the sequence of AcCRaV-Xho IR is: 5'-CCCTCGAGGGTCGACGAGCCGCAATACTT-3'.
[0017] Furthermore, the PCR amplification conditions in step (2) are:
[0018] The amplification system included: 2 μL template DNA, 2 μL AcCRaV-BamH IF, 2 μL AcCRaV-Xho IR, 25 μL 2× High-Fidelity Master Mix, 19 μL ddH2O;
[0019] The amplification program was as follows: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 62°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
[0020] The polyclonal antibody of kiwifruit ringspot virus prepared by the above method.
[0021] Application of the polyclonal antibody of kiwifruit ringspot virus prepared above in the detection of kiwifruit ringspot virus.
[0022] A kiwifruit ringspot virus detection reagent, a detection kit or a detection test paper, comprising the polyclonal antibody of the kiwifruit ringspot virus prepared by the above method.
[0023] The present invention has the following beneficial effects:
[0024] (1) The present invention uses a prokaryotic expression system to express the purified AcCRaV capsid protein as an antigen to prepare AcCRaV-CP polyclonal antibodies with an antibody titer of up to 1:1024000, indicating that the polyclonal antibodies of the present invention have high sensitivity, good specificity, and strong stability, providing an experimental basis for establishing a rapid, accurate, simple, and economical AcCRaV detection technology.
[0025] (2) There are only a few studies on the preparation of antibodies against kiwifruit virus, and there is no research on the preparation of polyclonal antibodies against AcCRaV. The project has developed polyclonal antibodies against AcCRaV, which are innovative and advanced in materials and technology, filling the gap in the preparation technology of polyclonal antibodies in the detection of kiwifruit AcCRaV virus.
[0026] (3) According to the characteristics of the AcCRaV genome, the present invention adopts a unique codon optimization method to adjust the codon adaptation index CAI (Codon Adaption Index) value to 0.98. The closer this value is to 1, the higher the protein expression of the exogenous protein in the host cell; and the GC content is adjusted to 57% to avoid the influence of excessive GC content on the expression efficiency. After codon optimization, the soluble expression of AcCRaV capsid protein was significantly improved.
[0027] (4) The AcCRaV genome is larger than that of ordinary viruses and has more mutations. This project selected a relatively conservative core segment of the capsid protein gene among many mutation sites to ensure the universality of the antibody. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the electrophoresis diagram of AcCRaV-CP target gene amplification;
[0029] Figure 2 Comparison of AcCRaV-CP sequence amplification results;
[0030] Figure 3 Codon optimization adaptation index for AcCRaV-CP;
[0031] Figure 4 GC content adjustment results for AcCRaV-CP codon optimization;
[0032] Figure 5 Alignment of protein sequences before and after codon optimization for AcCRaV-CP;
[0033] Figure 6 Construct the PCR electrophoresis diagram of bacterial solution for expression vector;
[0034] Figure 7 Construct sequencing results alignment for vectors;
[0035] Figure 8 The SDS-PAGE results for small amount of induced recombinant protein expression;
[0036] Fig. 9 The SDS-PAGE results of recombinant protein purified by Ni-NTA Resin;
[0037] Fig.10 This is the result of recombinant protein dialysis;
[0038] Fig.11 To detect antibody specificity by Western blot;
[0039] Fig.12 ELISA to detect the titer of AcCRaV-CP polyclonal antibody OD 450 value. DETAILED DESCRIPTION
[0040] The following examples are only used to explain the present invention and are not intended to limit the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0041] Embodiment 1:
[0042] Kiwifruit chlorotic ringspot-associated virus (AcCRaV) samples were collected from Dujiangyan City, Sichuan Province. New Zealand white rabbits were used as immunized animals. Escherichia coli ( Escherichia coli )DH5α, Escherichia coli ( Escherichia coli ) Rosetta (DE3) were purchased from Beijing Qingke Biotechnology Co., Ltd., and plasmid pET28a was purchased from Wuhan Miaoling Biotechnology Co., Ltd. The nucleic acid sequence was searched from the National Center for Biotechnology Information (NCBI), and the primers were designed using Primer Premier 5.0 software and synthesized by Sangon Biotechnology (Shanghai) Co., Ltd. The primer sequences used in this experiment are shown in Table 1.
[0043] Table 1 All primers used in this study
[0044]
[0045] (1) Weigh 0.2 g of kiwifruit leaves, add liquid nitrogen, anhydrous ethanol and an appropriate amount of reducing agent to grind, then transfer to a 2 mL EP tube, add 0.5 mL RNA extraction buffer and 0.5 mL phenol / methanol / alcohol solution, quickly mix on a vortex shaker, add 0.1 mL anhydrous ethanol, mix well, and place on ice for 15 minutes. Then centrifuge at 4°C, 10,000 rpm for 10 minutes.
[0046] (2) Transfer 400 μL of supernatant to a clean EP tube, add 2 times the volume of pre-cooled 4 mol / L LiCl solution, and place at -20°C for precipitation overnight.
[0047] (3) Take out the above reaction solution, centrifuge at 4℃, 10000rpm for 10min. Pour off the supernatant, wash with 70% pre-cooled ethanol and centrifuge twice, each time at 4℃, 10000rpm, centrifuge for 5min, place on the clean bench for several minutes, dry, dissolve in 30μL ddH2O for later use, or store at -20℃.
[0048] 2.2 RT-PCR amplification of target fragment
[0049] (1) cDNA preparation: After extracting total RNA from diseased leaves of kiwifruit infected with AcCRaV, cDNA was prepared using a reverse transcription kit purchased from Beijing Qingke. After the reaction was completed, the cDNA was stored on ice or at -20°C for later use.
[0050] (2) Target fragment amplification: PCR amplification system (25 μL): 1 μL cDNA, 1 μL AcCRaV-CP-F-933, 1 μL AcCRaV-CP-R-933, 12.5 μL 2× Taq Master Mix, 9.5 μL ddH2O;
[0051] PCR reaction program: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 54°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
[0052] (3) Agarose gel electrophoresis
[0053] Gel preparation (1% agarose gel): weigh 0.2g agarose and pour it into a small triangular bottle, add 20mL 1×TAE, heat in a microwave oven for 2-3min to fully dissolve the agarose, wait for the gel to cool to about 50°C, add 2μL nucleic acid dye and mix well, pour into the gel preparation plate, insert a comb, and after solidification, pull out the comb and put the gel into the electrophoresis tank containing 1×TAE electrophoresis buffer. The buffer must submerge the gel surface;
[0054] Sample loading: 5 μL of PCR product is applied to the gel well;
[0055] Electrophoresis: 120V, 120mA, 25min;
[0056] Photographing and result observation: Place the gel into the BIO-RAD gel imaging system, observe the results, take photos and save them, and send the product to Shanghai Sangon Biotechnology (Shanghai) Co., Ltd. for sequencing.
[0057] (4) AcCRaV-CP sequence amplification detection results
[0058] The electrophoresis results are as follows Figure 1 As shown, the amplification and sequencing results of the AcCRaV-CP sequence (as shown in SEQ ID NO.6) are compared as shown in Figure 2 shown.
[0059] The amplification gel electrophoresis diagram showed a bright, specific and single target band around 1000bp; the sequencing results showed that the sequencing results were 100% consistent. The test results showed that the target gene was successfully amplified.
[0060] (5) Codon optimization
[0061] After sequencing the above PCR products, the AcCRaV-CP-CDS sequence was obtained.
[0062] AcCRaV-CP-CDS amino acid sequence: MPKPMQGDASNSGSAVPSNVKIDPNTVKFGKKNSVRTITFTEVVNNRATSSKNSSNTAVSVFKSPAFVGGFTSDLDFDITKYYRVGSVETCASHLSNSQEIKKRLISDGFLELPISNNYSLFLCSEIQATSIENAVSFNKACAIMAY QILAHTVMEKYDWEQFKAVEVAIKDRKNPSISIVNRLAGQMRLPQSSLYYWMVVPGYEFLYDVFPIETIALTMVRLECRKALNIPEIITNAEIVNSLVSKMNRKHDLTKVSISEIITKLGVNNIKDMYNEFRRNVGTTGREIRNEHAVKEFLEFIGKYCGSST (SEQ ID NO.7).
[0063] The above sequence was codon optimized and the codon adaptation index CAI (Codon Adaption Index) value was adjusted to 0.98. Figure 3As shown in the figure, the closer this value is to 1, the higher the protein expression of the exogenous protein in the host cell; and the GC content is adjusted to 57%, such as Figure 4 As shown, in order to avoid the influence of too high GC content on expression efficiency, the AcCRaV-CP' sequence was obtained. The whole gene sequence synthesis was completed by Hangzhou Huaan Biotechnology Co., Ltd. The protein sequence remained unchanged after codon optimization. The protein sequence alignment results are shown in Figure 5 shown.
[0064] (6) Enzyme digestion and ligation of target fragment and plasmid
[0065] PCR reaction program: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 62°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
[0066] Table 2 Plasmid (pET-28a) digestion system 50μL digestion reaction components and dosage
[0067]
[0068] Table 3 Target fragment digestion system 50μL digestion reaction components and dosage
[0069]
[0070] Reaction conditions: 37°C, 15 min. After enzyme digestion, use DNA purification kit to recover.
[0071] Ligation using DNA Ligation Kit Ver.2.1 ligase:
[0072] Ligation system: Solution I 8μL; plasmid after restriction digestion 2μL; target fragment after restriction digestion 6μL.
[0073] Reaction conditions: Centrifuge and mix at 16°C for 1h30min. After completion, take 9μL, add 1μL Solution III, and use 10μL ligation solution to transform into E. coli DH5α.
[0074] (7) Transformation of recombinant plasmid into Escherichia coli DH5α
[0075] (8) Transformation of recombinant plasmid into Escherichia coli Rosetta (DE3)
[0076] The DH5α bacterial culture containing the recombinant plasmid pET28a-AcCRaV-CP-DJY1 that was previously sequenced and preserved was expanded and the plasmid was extracted using a plasmid extraction kit; the transformed strain was replaced with the protein expression strain Rosetta (DE3), and the subsequent transformation steps were the same as step (7).
[0077] 2.2 Expression and purification of AcCRaV-CP recombinant protein
[0078] The steps for inducing expression of a small amount of recombinant protein are as follows:
[0079] (1) Add 50 μL of the bacterial solution containing the recombinant plasmid to 5 mL of LB liquid medium (containing 50 μg / mL of kanamycin). The strain used is Rosetta (DE3). Place in a shaker and culture at 37°C and 160 rpm for 12 h.
[0080] (2) Add IPTG inducer to the cultured bacterial solution. No inducer was added to the control group, and IPTG was added to the experimental group to a final concentration of 1 mmol / L. The culture was placed in a shaker and cultured for 4 h at 37°C and 160 rpm.
[0081] (3) Remove the bacterial solution, centrifuge at 12,000 rpm for 10 min, discard the supernatant, add 1 mL of 1× PBS to resuspend the bacteria, mix thoroughly, and place on ice.
[0082] (4) Ultrasonic disruption was performed in an ice-water bath at 400 W, 5 s on, 5 s off cycle mode, with a working time of 1 min 20 s and a power of 12% until the bacterial solution was clear.
[0083] (5) Take 40 μL of bacterial lysate, add 10 μL of 5× protein sample buffer, boil in a boiling water bath for 10 min, and take 10 μL of sample for SDS-PAGE analysis.
[0084] (6) Use the SDS-PAGE denaturing acrylamide color gel rapid preparation kit to prepare protein separation gel and stacking gel of corresponding concentrations.
[0085] (7) Pour 1× electrode buffer into the protein electrophoresis tank, install the protein gel plate into the electrophoresis tank, gently remove the comb, and add samples to the loading wells in a certain order. The protein sample loading volume is 10 μL, and the marker loading volume is 5-7 μL.
[0086] (8) Turn on the power of the electrophoresis system and adjust the voltage to 80 V for 25 min. After the protein sample has passed through the concentrated gel, adjust the voltage to 120 V for 1 h 30 min until the protein sample reaches the bottom of the gel.
[0087] (9) After the electrophoresis, carefully remove the gel and place it in a container. Add 0.25% Coomassie Brilliant Blue staining solution and stain on a shaker for 30 min. Then pour out the staining solution and add destaining solution for three times, each time for more than 1 hour. Pour out the destaining solution, observe the bands with an imaging system, and analyze the results.
[0088] The experimental results showed that the Rosetta (DE3) strain containing the recombinant plasmid was induced with 1mmol / L IPTG and successfully expressed the target protein, with a molecular weight of 35.4 KDa, which was consistent with the expected size. Figure 8 shown.
[0089] The steps for inducing expression of large amounts of recombinant proteins are as follows:
[0090] (1) Add 3 mL of bacterial solution containing the recombinant plasmid to 300 mL of LB liquid medium (containing 50 μg / mL of kanamycin). The strain used is Rosetta (DE3). Place in a shaker and culture at 37°C and 160 rpm for 12 h.
[0091] (2) Add IPTG inducer to the cultured bacterial solution to a final concentration of 1 mmol / L, place in a shaker, and continue culturing at 37°C, 160 rpm for 4 h.
[0092] (3) Remove the bacterial solution and centrifuge at 12,000 rpm for 10 min. Discard the supernatant and collect the bacteria in a centrifuge tube. Resuspend the bacteria in 10 ml of 1× PBS and disrupt them by ultrasonication at 100 W for 16 min in an ice water bath.
[0093] (4) Centrifuge at 4°C, 12000 rpm for 10 min, collect the precipitate and supernatant separately. Keep 20 μL of the supernatant for SDS-PAGE electrophoresis; resuspend the precipitate with 10 ml of 8 mol / L urea solution, continue ultrasonication at 100 W for 10 min in an ice water bath, and keep 20 μL for SDS-PAGE electrophoresis. The rest of the sample is used for protein purification.
[0094] The protein was purified by affinity chromatography column and the purification scheme of Ni-NTA Resin purification with His-tagged protein (non-denaturing) was used for purification. The purification steps of the recombinant protein are as follows:
[0095] (1) Wash the column once with 5 mL of deionized water.
[0096] (2) Equilibrate once with 5 mL of non-denaturing washing buffer (8 mol / L urea, 250 mmol / L NaCl, 250 mmol / L imidazole in 0.01 mol / L PBS).
[0097] (3) Load the sample and repeat the loading once. Collect the flow-through and keep 20 μL for SDS-PAGE electrophoresis.
[0098] (4) Wash the column with 5 mL of 1× PBS, collect the washing solution and retain 20 μL for SDS-PAGE electrophoresis.
[0099] (5) Elute the protein with 5 mL of non-denaturing Washing Buffer, collect the eluate 1 and retain 20 μL for SDS-PAGE electrophoresis.
[0100] (6) Elute the protein with 5 mL of non-denaturing 60 mM imidazole eluent. Collect eluate 2 and retain 20 μL for SDS-PAGE electrophoresis.
[0101] (7) Elute the protein with 5 mL of non-denaturing 60 mM imidazole eluent. Collect the eluate 3 and retain 20 μL for SDS-PAGE electrophoresis.
[0102] (8) Wash the column with 5 mL of 0.5 M NaOH.
[0103] (9) Wash the column three times with 5 mL of deionized water.
[0104] (10) Equilibrate the column with 20% ethanol and store it.
[0105] (11) Store the penetration solution, washing solution and elution solution in a refrigerator at 4°C. After the electrophoresis test results are available, dialyze the elution solution containing the target protein. If the penetration solution still contains a large amount of target protein, it can be used as a sample for a second purification.
[0106] The Rosetta (DE3) strain containing the recombinant plasmid was induced to express a large amount of recombinant protein, and the recombinant protein was purified using Ni-NTA Resin, such as Fig. 9 As shown, the elution bands in lanes 3-5 are single and have the correct molecular weight, indicating that the recombinant protein has been successfully purified and can be used for subsequent dialysis experiments.
[0107] The dialysis steps of the recombinant protein are as follows:
[0108] The recombinant protein expressed in the supernatant was purified by Ni column and the eluate obtained was placed in a dialysis bag and dialyzed using 0.01 mol / L PBS. 20 μL of the sample was retained for SDS-PAGE electrophoresis detection and the dialyzed protein was aliquoted and stored in a -80°C ultra-low temperature refrigerator.
[0109] The results of SDS-PAGE were as follows: Fig.10 As shown, it shows that the recombinant protein obtained by dialysis is of the correct size and has a high purity.
[0110] 2.3 Preparation of AcCRaV-CP polyclonal antibodies
[0111] The purified recombinant protein was sent as an antigen to Hangzhou Huaan Biotechnology Co., Ltd. to immunize New Zealand white rabbits to prepare AcCRaV-CP polyclonal antibodies and purify them to obtain AcCRaV-CP polyclonal antibodies.
[0112] Experimental Example 1: Western blot detection of AcCRaV-CP polyclonal antibodies
[0113] Western blot was used to detect the prepared AcCRaV-CP polyclonal antibody. SDS-PAGE electrophoresis was performed first, and then the gel was taken out and transferred to a membrane, incubated with antibodies and imaged to complete the verification of Western blot.
[0114] Take out 40 μL of purified recombinant protein from the -80°C refrigerator, freeze-thaw on ice, add 10 μL of 5× protein loading buffer, boil at 95°C for 5 min, and centrifuge at 12000 rpm for 1 min as the spot sample.
[0115] (1) Prepare protein gel according to the size of the target protein, and use the SDS-PAGE denatured acrylamide color gel rapid preparation kit to prepare protein separation gel and stacking gel of corresponding concentration.
[0116] (2) Add 1× electrode buffer to the electrophoresis tank, first check whether there is leakage between the protein gel glass plates, and remove the comb in the buffer. Add protein samples to the sample wells in a certain order, and add protein marker to one of the wells.
[0117] (3) Turn on the power and adjust the voltage to the program of s1: 80 V, 25 min, s2: 120 V, 1 h 30 min, until the bromophenol blue indicator runs to the bottom of the gel.
[0118] (4) After electrophoresis is completed, remove the remaining pores and the lower blue indicator portion of the other gel for membrane transfer.
[0119] 3. Transfer
[0120] (1) Take a PVDF membrane according to the size of the glue. The membrane should be slightly larger than the glue. Soak the PVDF membrane in anhydrous methanol to activate the membrane for 1 to 2 minutes until it becomes translucent.
[0121] (2) Place the sponge, three layers of filter paper, glue, and membrane in a porcelain dish containing 1× transfer solution and soak for 30 minutes.
[0122] (3) Assemble the "sandwich": Start from the black side (negative electrode) of the plate and place them in the following order: sponge - three layers of filter paper - glue - membrane - three layers of filter paper - sponge. After each layer is placed, use a smooth glass coating rod to remove bubbles.
[0123] (4) Place the "sandwich" in the transfer tank (black side facing black side), add 1× transfer solution, plug in the electrodes, and run the electrophoresis in an ice bath at 100V, 200mA, 40min. (The voltage and electrophoresis time can be adjusted according to the molecular weight of the protein).
[0124] (5) After the film transfer is completed, turn off the power and remove the film (with the adhesive side facing up).
[0125] 4. Blocking, Incubation, and Imaging
[0126] (1) After the transfer is completed, immediately place the protein membrane in the prepared TBST and rinse twice to remove the transfer solution. Then add 5% skim milk blocking solution and shake it in a room temperature shaker for 1 hour. Place it in a rotary shaker at 4°C overnight.
[0127] (2) Primary antibody incubation
[0128] ① Take out the membrane incubated overnight at 4°C and shake it on a shaker at room temperature for 1 hour.
[0129] ②Preparation of primary antibody solution: 1μL primary antibody + 10mL blocking solution.
[0130] ③Add primary antibody solution and incubate on a shaker at room temperature for 1 hour.
[0131] ④After incubation, wash the membrane three times with TBST, 10 min each time.
[0132] (3) Secondary antibody incubation
[0133] ① Preparation of secondary antibody solution: 2 μL of HRP-labeled goat anti-rabbit + 10 mL of blocking solution.
[0134] ②Add secondary antibody solution and incubate on a shaker at room temperature for 1 hour.
[0135] ③After incubation, wash the membrane three times with TBST, 10 min each time.
[0136] (4) Color development and imaging
[0137] ① After incubation with secondary antibody and washing the membrane, place the membrane in 1×TBS and develop with Ecl chemiluminescent colorimetric solution. Use 1mL of colorimetric solution for each membrane (500μL each of solution A and solution B). Be careful to avoid light.
[0138] ② Use a gel imaging system to perform imaging, adjust exposure conditions according to different light intensities, and observe the results.
[0139] The test results are as follows Fig.11 As shown, the AcCRaV-CP polyclonal antibody obtained by immunization was diluted at a concentration of 1:10000 and subjected to Western blot detection with the purified recombinant protein. The results showed that the antibody had a specific immune reaction with the purified recombinant protein, and the band was single, indicating that the antibody had high specificity and could recognize the AcCRaV-CP protein.
[0140] Experimental Example 2: ELISA method to detect the titer of AcCRaV-CP polyclonal antibody
[0141] (1) Plate coating: Dilute the antigen to 1 μg / mL with PBS, prepare a 96-well ELISA plate, add 100 μL of antigen to each well, set up a blank control, set up duplicate wells, and coat overnight at 4°C.
[0142] (2) Washing: The next day, discard the solution in the wells, add 220 μL PBST to each well, wash three times, and remove the washing solution; each time for 5 minutes.
[0143] (3) Blocking: Add 100 μL of blocking solution (1% BSA) to each well and incubate in a 37°C incubator for 2 h.
[0144] (4) Washing the plate: Pour out the blocking solution, add 220 μL PBST to each well, wash three times, and remove the washing solution. Each wash is for 5 minutes.
[0145] (5) Primary antibody incubation: Add primary antibody diluted in PBST at 1:250, 1:1000, 1:4000, 1:16000, 1:64000, 1:256000, and 1:1024000, 100 μL per well and incubate at 37°C for 2 h.
[0146] (6) Washing the plate: Pour out the primary antibody reaction solution, add 220 μL PBST to each well on average, wash three times, and remove the washing solution; each time for 5 minutes.
[0147] (7) Enzyme-labeled secondary antibody incubation: Dilute HRP-labeled goat anti-rabbit IgG to 1:5000 with PBST, add 100 μL to each well, and incubate in a 37°C incubator for 1 h.
[0148] (8) Washing the plate: Pour out the secondary antibody reaction solution, add 220 μL PBST to each well on average, wash three times, and remove the washing solution; each time for 5 minutes.
[0149] (9) Substrate color development: Add 100 μL of TMB color development solution to each well and incubate in a 37°C incubator in the dark for 15 to 30 minutes.
[0150] (10) Termination: When color development begins, terminate the reaction and add 100 μL of 2 mol / L H2SO4 termination buffer to each well to change the blue color to yellow. Then use an ELISA reader to measure and read the value at 450 nm. Save the data and analyze it. A value that is 2.1 times that of the blank control is considered positive.
[0151] 2. Test results
[0152] The results of the ELISA test for the titer of the AcCRaV-CP polyclonal antibody are shown in Table 4 and Fig.12 shown.
[0153] Table 4 P / N value of AcCRaV-CP polyclonal antibody titer
[0154]
[0155] AcCRaV-CP polyclonal antibody was diluted to 1:250, 1:1000, 1:4000, 1:16000, 1:64000,
[0156] After dilution with concentrations of 1:256000 and 1:1024000, the antibody titer was detected by ELISA with the purified target protein. After the ELISA operation, the OD value at a wavelength of 450nm was read in an ELISA reader, and the average of 3 replicates was calculated. The standard deviation was considered, and the P / N value was calculated. P refers to the average OD450 of each sample, and N refers to 2.1 times the OD450 of the blank control sample. A value higher than 2.1 times the blank control is positive, that is, a P / N value greater than 1 is positive, and a value less than 1 is negative. From the ELISA results, it can be seen that the antibody titer reaches more than 1:1024000, indicating that the antibody titer is very high and of good quality.
[0157] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a polyclonal antibody against kiwifruit ringspot virus, characterized in that: The following steps are involved: (1) Preparing template DNA using total RNA from kiwifruit infected with kiwifruit ringspot virus; (2) Using the template DNA prepared in step (1) as a template, PCR amplification was performed using the AcCRaV-BamH IF / Xho IR primers to amplify the AcCRaV-CP target gene fragment; (3) Connecting the AcCRaV-CP target gene fragment to the expression vector to obtain a recombinant vector, and then transfecting the recombinant vector into Escherichia coli to induce protein expression and purification to obtain the recombinant protein; (4) using the recombinant protein obtained in step (3) to prepare polyclonal antibodies against kiwifruit ringspot virus; The specific process of step (1) is as follows: using the total RNA of kiwifruit infected with kiwifruit ringspot virus as a template, reverse transcription is performed to prepare cDNA, AcCRaV-CP-F-933 / AcCRaV-CP-R-933 primers are used for PCR amplification, and the amplified product is codon optimized, the codon adaptation index is adjusted to 0.98, and the GC content is adjusted to 57%, so as to obtain template DNA; the sequence of the template DNA is shown in SEQ ID NO.1; the sequence of AcCRaV-CP-F-933 is shown in SEQ ID NO.2, and the sequence of AcCRaV-CP-R-933 is shown in SEQ ID NO.3; In step (2), the sequence of AcCRaV-BamH IF is shown as SEQ ID NO.4, and the sequence of AcCRaV-Xho IR is shown as SEQ ID NO.
5.
2. The method for preparing a polyclonal antibody against kiwifruit ringspot virus according to claim 1, characterized in that: The PCR amplification conditions in step (1) are: The amplification system included: 1 μL cDNA, 1 μL AcCRaV-CP-F-933, 1 μL AcCRaV-CP-R-933, 12.5 μL 2× Taq Master Mix, 9.5 μL ddH2O; The amplification program was as follows: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 54°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
3. The method for preparing a polyclonal antibody against kiwifruit ringspot virus according to claim 1, characterized in that: The PCR amplification conditions in step (2) are: The amplification system included: 2 μL template DNA, 2 μL AcCRaV-BamH IF, 2 μL AcCRaV-Xho IR, 25 μL 2× High-Fidelity Master Mix, 19 μL ddH2O; The amplification program was as follows: pre-denaturation at 94°C for 3 min, denaturation at 94°C for 30 s, annealing at 62°C for 30 s, extension at 72°C for 1 min, 34 cycles, termination extension at 72°C for 10 min, and storage at 12°C.
4. A polyclonal antibody against kiwifruit ringspot virus prepared by the method according to any one of claims 1 to 3.
5. Use of the polyclonal antibody against kiwifruit ringspot virus according to claim 4 in the detection of kiwifruit ringspot virus.
6. A kiwifruit ringspot virus detection reagent, detection kit or detection test paper, characterized in that: The invention comprises the polyclonal antibody against the kiwifruit ringspot virus according to claim 4.
Citation Information
Patent Citations
Visual detection method for kiwifruit chlorotic ringspot virus based on immune colloidal gold
CN114910645A
Primer pair, primer group, kit and method for detecting kiwifruit chlorotic ringspot virus
CN116083642A
Diagnostic methods for virus
JP2019013169A
